The Group in summary
|
|
| Full year |
| Full year |
| ||
|
- |
|
- |
| 2023 |
| 2022 |
|
Net sales | 1 626 |
| 3 884 |
| 8 015 |
| 9 684 |
|
Operating result | -20 823 |
| -23 394 |
| -93 579 |
| -64 413 |
|
Result after financial items | -19 880 |
| -23 045 |
| -91 464 |
| -64 155 |
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities | -10 134 |
| -18 974 |
| -45 834 |
| -69 790 |
|
Cash flow for the period | -10 305 |
| -19 262 |
| 42 642 |
| -70 013 |
|
|
|
|
|
|
|
|
|
|
Balance sheet total | 259 611 |
| 265 035 |
| 259 611 |
| 265 035 |
|
Equity ratio | 92% |
| 94% |
| 92% |
| 94% |
|
|
|
|
|
|
|
|
|
|
Number of shares outstanding end of period | 75 736 264 |
| 50 490 843 |
| 75 736 264 |
| 50 490 843 |
|
Average number of shares before dilution | 75 736 264 |
| 50 490 843 |
| 60 963 017 |
| 50 295 324 |
|
Average number of shares after dilution | 75 736 264 |
| 50 490 843 |
| 60 963 017 |
| 50 406 868 |
|
Earnings per share before dilution | -0,33 |
| -0,46 |
| -1,69 |
| -1,28 |
|
Earnings per share after dilution | -0,33 |
| -0,46 |
| -1,69 |
| -1,28 |
|
Figures in brackets indicate outcome for the corresponding period of the previous financial year. The financial information presented relates to the Group and is expressed in TSEK unless otherwise stated.
CEO Comments
During the fourth quarter, an Extraordinary General Meeting was held, which, in accordance with the proposed agenda, decided to completely change the board of directors. The sales efforts for Strangvac in
Extraordinary General Meeting
The Extraordinary General Meeting decided, in accordance with the proposal from the shareholder group, that the board of directors shall consist of five board members without deputies. The general meeting appointed Håkan Björklund (chairman),
Strangvac
The sales work in
During the quarter, the focus has been on sales efforts in
Sales volumes remain modest, and variations between months persist, but they are now at a slightly higher and more stable level than before. We have noted increased interest in Strangvac from both veterinarians and horse owners in the market.
On
Our activities continue to prioritise education on both strangles and our vaccine, aiming to increase confidence in both veterinarians and horse owners regarding the use of Strangvac.
Due to Covid, the
The manufacturing of biological pharmaceuticals is complex, and we have continued to allocate resources toward developing and improving analysis methods and manufacturing processes with our contracted external manufacturers and partners. These enhanced analysis methods have reduced the risk of disruptions in the manufacturing process, positively impacting the company's ability to generate revenue and profitability.
The company's goals and expectations regarding Strangvac remain unchanged: to establish Strangvac as a standard vaccination for horses.
Project portfolio
The proof-of-concept study conducted during spring 2023 regarding a vaccine for mastitis in dairy cows, caused by the bacterium Staphylococcus aureus, did not achieve statistical significance in terms of protective efficacy, as previously announced. The company has no plans to conduct any further studies in this project during 2024.
In the fourth quarter, the United States Patent and Trademark Office granted our patent application for a vaccine against Streptococcus suis infections in pigs. Additionally, in collaboration with Moredun Scientific, we have received funding from the Eurostars 3 program to further develop
The vaccine development project, spanning three years with a total budget of approximately
This significant grant from Eurostars, in conjunction with Vinnova, provides additional evidence of the potential societal benefits from our vaccine technology. By improving animal health, reducing the need for antibiotics, and contributing to enhanced profitability for farmers, our work has the potential to make a positive impact. Streptococcus suis is a scourge for pig populations worldwide, and it's fantastic that we have received support from these influential organizations to take this important step forward.
The capital raised through the new share issue in June provides the company with the means to operate satisfactory throughout 2024. To accelerate the sales development of Strangvac and drive the company's long-term growth, we will now begin strengthening our financial position.
The company has previously reported a future potential for Strangvac, without specifying when this would be possible. Such potential, even if feasible, is difficult to translate into a relevant financial goal. Therefore, the company will not currently set any financial targets, either short-term or long-term. The focus now will be on efficient sales and production of our Strangvac vaccine.
The company intends to appoint a permanent CEO during the first quarter of 2024.
CEO
Certified adviser
Eminova Fondkommission is
Biblioteksgatan 3, 3 tr.
114 46 Stockholm
Tel: +46 8 684 211 10
adviser@eminova.se
Dividend
The Board of Directors proposes that no dividend be paid.
Dates for upcoming reports
Interim report Q1 | |
Interim report Q2 | |
Interim report Q3 | |
Year-end report |
Annual report 2023 will be published on
Annual General Meeting
Annual General Meeting 2024 will take place on
Contact information
Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73
E-mail: jonas.sohlman@intervacc.se
The company is organizing a teleconference on
The year-end report for the period January -
This information is information that
About
https://news.cision.com/intervacc/r/year-end-report-january---december-2023,c3929986
https://mb.cision.com/Main/4632/3929986/2609705.pdf
https://news.cision.com/intervacc/i/q4-2023-en,c3268325
(c) 2024 Cision. All rights reserved., source